A Class Action Suits Moves RICO from Mobsters to Medicine

Episode Summary

Executive Summary: The episode examines a landmark civil RICO class action against Takeda and Eli Lilly over Actos, alleging a long-running scheme to conceal bladder-cancer risks from regulators, physicians, and payers. Attorney Harrison James explains how RICO applies beyond organized crime, why this case cleared major causation and class-certification hurdles, and why it could influence pharmaceutical disclosure, payer recovery, and future fraud litigation.

Main Topics: RICO’s scope beyond organized crime (Priority: 5/5): James explains that RICO prohibits conducting an enterprise through a pattern of racketeering activity, commonly mail and wire fraud, and has been broadly applied to healthcare and commercial fraud because the statute’s text is not limited to mob activity. Actos litigation and alleged concealment of bladder-cancer risk (Priority: 5/5): The case centers on claims that Takeda and Lilly knew of bladder-cancer signals before and after approval of Actos, minimized them to the FDA and physicians, and protected sales despite internal awareness that a warning would hurt prescribing. Why the case qualifies as civil RICO (Priority: 5/5): The alleged coordinated conduct between Takeda and Lilly forms the required enterprise, with repeated communications and shared decision-making about safety information, labeling, and marketing supporting the racketeering theory. Proximate cause and the role of physicians (Priority: 5/5): The Ninth Circuit held that physicians are foreseeable intermediaries rather than independent breaks in the causal chain, allowing third-party payers and patients to show direct economic injury from the alleged fraud. Class certification and common proof (Priority: 4/5): The court certified a national third-party payer class because injury and causation could be shown with common evidence such as regression analysis, internal documents, and peer-reviewed literature, rather than individualized proof. Industry implications and limits of the ruling (Priority: 4/5): James argues the case should not chill good-faith scientific debate, but it does warn companies that suppressing or selectively disclosing material safety information to protect sales can create serious liability exposure.

Key Arguments: RICO is not confined to organized crime; courts have repeatedly applied it to large-scale fraud in regulated industries when the statutory elements are met. Civil RICO is attractive because it allows treble damages, attorney’s fees, nationwide service of process, and does not require the same direct-reliance showing as common-law fraud. The Actos case is unusually strong because it involves a single drug, a coherent economic-injury theory, and substantial internal evidence plus econometric analysis. Takeda and Lilly allegedly coordinated over years to downplay bladder-cancer risk, despite internal awareness that a warning would materially reduce prescribing and sales. The Ninth Circuit rejected the argument that physicians’ prescribing judgment breaks causation, treating them as foreseeable intermediaries in a prescription-drug market. Class certification succeeded because common evidence could prove injury and causation across the class, and the class definition largely avoided uninjured members. The case is procedurally advanced but still contested, with a certiorari petition pending and additional district-court motions still being litigated. The broader lesson for pharma is that good-faith uncertainty is not the problem; intentional suppression or reframing of safety data to protect revenue is what creates RICO risk.

Data Points: Actos market launch: 1999 - The diabetes drug Actos came onto the market in 1999. FDA warning added: 2011 - FDA eventually forced Takeda to add a bladder-cancer warning to Actos in 2011. MDL filing period: 2013-2014 - The litigation began as part of a multi-district litigation filed around 2013 or 2014. Ninth Circuit reversal on proximate cause: 2018 - The Ninth Circuit reversed the district court on proximate causation in 2018. Class certification motion: 2021 - The plaintiffs moved for class certification in 2021. Class certified: 2023 - The national third-party payer RICO class was certified in 2023. Punitive damages verdict: $9 billion - A prior personal-injury trial in the MDL produced a $9 billion punitive damages verdict against Takeda and Lilly before reduction. Estimated collective profit during class period: over $24 billion - James said the companies collectively profited over $24 billion during the damages/class period. Potential treble verdict exposure: could exceed $7 billion - He referenced a possible treble-damages verdict that could exceed an estimated $7 billion.

Pivotal Quotes: "RICO is, you're talking exclusively about economic damages." — Harrison James: Explaining why civil RICO is aimed at financial injury rather than personal injury claims. "Physicians are foreseeable intermediaries. They're not independent intervening causes." — Harrison James: Describing the Ninth Circuit’s proximate-cause ruling in the Actos case. "It should not be subservient to marketing." — Harrison James: Summarizing the line between legitimate pharmacovigilance and actionable fraud.

Implications: The case signals that pharma companies may face RICO exposure when they allegedly suppress safety risks to protect sales. It also gives payers a potential recovery path for economic losses tied to misleading drug promotion.